It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...

Omvoh is now approved in the U.S. for two types ... 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early ...

Yet, unlike its IL-23p19 predecessors — Skyrizi (risankizumab, AbbVie) and Omvoh (mirikizumab, Eli Lilly & Co.) — Tremfya is the only one to demonstrate clinical superiority to the IL-12/23 ...

In addition to both tirzepatide brands, Lilly expects increasing contributions from four recently launched therapies: Jaypirca, Ebglyss, Omvoh, and Kisunla. It also looks like this big pharma ...

Sales of Zepbound, administered via a weekly injection, are soaring, but a potential competitor from Viking Therapeutics (NASDAQ: VKTX) has been gaining a lot of attention. Mid-stage clinical ...

Eli Lilly’s Omvoh became the first IL-23 drug approved in ulcerative colitis in October 2023, while AbbVie’s Skyrizi hit the scene as the first IL-23 med cleared by the FDA to treat Crohn’s ...

Lilly’s Omvoh was approved for UC in the United States, Europe and Japan in 2023. Omvoh was approved for CD in the United States in January 2025, while applications are under review in Europe ...